Stockscreener 앱 받기
9.05
5.97%
0.51
시장 영업 전:
9.18
0.13
+1.44%
Emergent Biosolutions Inc 주식(EBS)의 최신 뉴스
Travel Vaccines Market Size is Projected to Reach US$ 5,914.22 - openPR.com
SAB Biotherapeutics and Emergent BioSolutions Sign Manufacturing and Supply Agreement for Drug Product Development - Minichart
Emergent BioSolutions Announces Preliminary 2012 Financial Results and Provides Guidance for 2013 - AOL.com
Emergent BioSolutions director Keith Katkin sells $128,182 in stock By Investing.com - Investing.com Australia
Singapore approves Emergent's ACAM2000 for high-risk mpox use - Stock Titan
Emergent BioSolutions director DeGolyer sells $129,993 in shares By Investing.com - Investing.com India
Emergent BioSolutions director Dayal sells $115,610 in stock - Investing.com
Emergent BioSolutions director Keith Katkin sells $128,182 in stock - Investing.com
Emergent BioSolutions (NYSE: EBS) director nets stock awards, tax-driven share sales - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives new grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares and receives RSUs, options - Stock Titan
Director Marvin White (NYSE: EBS) receives RSU and stock option awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options for board service - Stock Titan
Director at Emergent BioSolutions (NYSE: EBS) receives RSU and option grants - Stock Titan
Emergent BioSolutions (NYSE: EBS) director sells shares, receives new awards - Stock Titan
Emergent BioSolutions (EBS) director granted RSUs and stock options in annual award - Stock Titan
Emergent BioSolutions (NYSE: EBS) chair granted RSUs and stock options as board pay - Stock Titan
Emergent BioSolutions Secures Long-Term Strategic Manufacturing Contract with SAB Biotherapeutics to Advance Type 1 Diabetes Candidate, SAB-142 - Bioscience Association Manitoba
H.C. Wainwright Maintains Emergent BioSolutions(EBS.US) With Buy Rating, Maintains Target Price $12 - Moomoo
MSN Money - MSN
Emergent BioSolutions (EBS) Q1 EPS Profit Challenges Narrative Of Persistent Losses - Sahm
Emergent BioSolutions Earnings Call Highlights Turnaround Momentum - The Globe and Mail
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer LINDAHL RICHARD S - Moomoo
Emergent BioSolutions | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer PAPA JOSEPH C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Perl Jessica - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Hartzel William - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Lowry Simon C - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Glessner Coleen - Moomoo
Emergent BioSolutions | 4: Statement of changes in beneficial ownership of securities-Officer Williams Paul Anthony - Moomoo
Emergent BioSolutions Shares Turnaround Update at 2026 Annual Meeting; All Proposals Approved - MarketBeat
Emergent BioSolutions Inc. 2026 Q1ResultsEarnings Call Presentation (NYSE:EBS) 2026-05-02 - Seeking Alpha
Emergent BioSolutions Q1 2026 Financial Results: Earnings, Revenue, and Key Risk Factors Explained - Minichart
Emergent BioSolutions Posts Weak Q1 Results Amid Turnaround - The Globe and Mail
Emergent BioSolutions (EBS) SVP awarded 100,111 restricted stock units under amended plan - Stock Titan
Emergent BioSolutions (EBS) awards 100,111 RSUs to R&D CMO - Stock Titan
Emergent BioSolutions (NYSE: EBS) awards 100,111 RSUs to EVP - Stock Titan
Emergent BioSolutions (EBS) CFO receives 162,680 restricted stock units - Stock Titan
Emergent BioSolutions (EBS) SVP awarded 104,282 restricted stock units - Stock Titan
SVP at Emergent BioSolutions (NYSE: EBS) receives 100,111 RSUs - Stock Titan
Emergent BioSolutions (NYSE: EBS) CEO gets 187,708 RSUs over 3 years - Stock Titan
[144] Emergent BioSolutions Inc. SEC Filing - Stock Titan
Emergent (EBS) Q1 2026 Earnings Transcript - The Globe and Mail
Emergent Biosolutions Q1 2026 earnings preview - MSN
Q1 2026 Emergent BioSolutions Inc Earnings Call Transcript - GuruFocus
Emergent BioSolutions Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Emergent Biosolutions Q1 Earnings Call Highlights - MarketBeat
Emergent BioSolutions Inc (EBS) Q1 2026 Earnings Call Highlights - GuruFocus
Emergent BioSolutions Q1 2026 slides: revenue tops guidance amid turnaround - Investing.com Australia
Emergent Biosolutions (NYSE:EBS) Posts Quarterly Earnings Results, Beats Expectations By $0.46 EPS - MarketBeat
Emergent BioSolutions Q1 2026 slides: revenue tops guidance amid turnaround By Investing.com - Investing.com South Africa
Emergent BioSolutions (NYSE:EBS) Surges After Q1 Earnings Beat and Raised Profit Outlook - ChartMill
Emergent Biosolutions (EBS) Reports Strong Q1 Earnings with Upda - GuruFocus
Is Emergent BioSolutions (EBS) Overvalued After Q1 2026 Earnings - GuruFocus
Earnings call transcript: Emergent BioSolutions Q1 2026 exceeds revenue expectations - Investing.com
Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript - Benzinga
Emergent BioSolutions (NYSE: EBS) Q1 2026 results show 30% revenue drop - Stock Titan
Emergent Biosolutions: Q1 Earnings Snapshot - marketscreener.com
Emergent BioSolutions (EBS) Stock Rises on Q1 2026 Earnings - Quiver Quantitative
0.67%
2.13%
자본화:
|
볼륨(24시간):